NCT07507435Not yet recruiting
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV)
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs). OPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate. The trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 480 (estimated)
- First submitted
- 26 Mar 2026
- Start date
- Sept 2026
- Primary completion date
- Mar 2029
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Diseases
- HIV
- NCT number
- NCT07507435
What you commit to
- Study type: Interventional
- Planned participants: 480
- From Sept 2026 to the primary completion date, Mar 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- If a non-VA provider is the main primary care or HIV provider
Other
- Enrolled in palliative care or hospice
- Are currently participating in a separate ongoing interventional clinical trial
Who the study is looking for
- PWH with an active prescription of ART any time in past 6 months and \<200 copies/mL within past 12 months, actively receiving care at the VA, and one of the following:
- Actively smoking
- Prescribed ICS for \>90 days
- Prescribed a PPI for \>90 days
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Boise VA Medical Center Coordinator of this site? Confirm its status | Boise | United States | Unknown status |
| Minneapolis VA Health Care System Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| VA Puget Sound Health Care System Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.